|
Post by cjc04 on Jul 12, 2016 17:03:48 GMT -5
Thank you, I've thought of that and may in the future, but not right now. If you're not aware of my back story, my wife is in the medical field and switched to an endo she knows who wrote her the script simply because he trusts her, not because he knew much about Afrezza. He is impressed with her A1c but I think he's waiting to see what happens. I educated him from day 1, so if he were to be approached it would be obvious that it came from me. Too many work relationships involved for me to do that right now. np. Mike has the data of prescribers and your doc will be in that too.. And I think that list is priority for Mike's team Impressed? he better be singing Afrezza soon to all of his patients for his patients A1c sake. I totally agree with you,,,, let's just hope some of these endos are making decisions for their patients sake. This is an ugly business, I can't imagine what is being said about Afrezza by all the smooth talking BP reps, including Sanofi.
|
|
|
Post by lakers on Jul 12, 2016 18:58:26 GMT -5
surplus.value • 3 hours ago 14users liked this postsusers disliked this posts0Reply MNKD presentation today at Cantor Mike presented (dont know what happened to Matt?) -Funds until Q1 2017 -10 million /month burn rate -7-8 out of 10 patients are being approved by insurance .. very positive -Coverage by Aetna and Express already , CVS and UNITED coming along, Medicare slower and will be about 1.5 years before medicare is fully present (process takes much longer) - are targeting 3/4 of diabetes market -protocols for pediatric should be ready before end of 2016 may facilitate use in externals markets as an inroad. - use two of the studies presented at ADA to push for a label change -July 25 or earlier MNKD's own product will be distributing (and 100% goes to MNKD) Some issue with Sanofi's supply which has 6 month expiry (DEC) so some issue with pharmacies stocking it. Will speak to Sanofi and also MNKDs own supply will be now used. -Spirometry not a problem , being taken care of . -- MNKD own patient reimbursement program launching Aug 1 and is well organized (online) "MNKD cares" -Late August sample packs for new adopters and will have sufficient supply dosages to offset any problems with lasting for early patients - 180 count titration packs to also deal with new patients running out 60's of 4, 8, 12 (180 total) and 90 count packs of 8 and 12 -Price renegotiation revisited as demand and sales increase. -Not looking for partner in US -working on foreign deal but good deal difficult until US sales ramp up. - should see script numbers bottom out in july and start to increase in next few months August and onwards -Controlling costs - still pursuing Technosphere applications ( 3 main ones already discussed previously ) which are not costing much now and seeking partners for these - End of year milestone payment coming but cant discuss due to NDA Thats all I managed to write down. Mike knows what hes doing. Very confident. Finally MNKD has someone on the ball. Also from memory. -ADA went really well. MNKD booth was solidly busy for 3 days. Countered the false assumption that MNKD was disappearing from the market - Mike said something about speaker programs (something to do with widening awareness of Afrezza in the general market. -Mike is not worried about coverage but continues to be in contact and discussion withpayers/insurance etc. _ Mike is keeping his ear close to the ground keeping in touch with sales personell, nurses etc. finance.yahoo.com/mbview/threadview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1468354989952-0afbea59-b93c-40e7-9690-0bd4a9034292&tls=la%2Cd%2C2%2C3
|
|
|
Post by agedhippie on Jul 12, 2016 19:07:34 GMT -5
Hello all, a little personal update.... Re Tresiba So a few months ago my wife (40, T1) switched from Trajeo to Tresiba on my recommendation. That change, along with Afrezza of course, gave her the greatest control of her bs she's ever had. Unfortunately, it came with weight gain that she couldn't control. She was 5'8" around 145 and she gained over 10 lbs. After talking with her Endo yesterday, she's switching back to Trajeo. Just an FYI,,, apparently this is a well known issue with Tresiba. I'm curious if anyone else knows of any experiences like this. Oh, and he also told her that he hasn't written any other scripts for Afrezza because he heard it wouldn't be available any more. I really don't understand how little ol MNKD is going to survive in the viscous BP world. Forgive me as I don't understand the weight gain part. Why is it common to gain weight? I have taken medication that made me want to eat more and I did and gained weight. It's because diabetes is caused by an insulin deficiency - relative deficiency for Type 2 and absolute deficiency for Type 1, so the body cannot efficiently move glucose from the blood for energy. The body's response to an glucose deficit is to make you eat more which is problematic for diabetics because it means they overeat since only a percentage of the glucose gets through and the rest gets stuck in the blood and taken out by the kidneys. Now you start adding external insulin - suddenly the glucose is no longer getting trapped and your numbers improve. You now have enough for your energy requirements plus extra to store away as fat and you gain weight. Eventually the body recalibrates and the weight gain slows but by then you are several pounds past where you used to be. Diet and weight gain are finely balanced for insulin users because insulin with it's IGF-1 link is such a powerful hormone. Most of the weight gain from insulin is fat but some is muscle and that comes from the IGF-1 side (some bodybuilders take insulin for weight gain). Weight gain is commonly associated with improved HbA1c and you often see it when people go on pumps for the first time. The flip side is weight loss from diabulimia which is mostly Type 1 where you reduce insulin to increase glucose levels and skirt the edge of DKA. This turns loose ketosis that has about as much similarity to the ketosis you see in Atkins as a sabre toothed tiger has to a pussy cat. You can eat like a horse (actually you have to) and lose 10% of your bodyweight in a couple of weeks. Needless to say this is extremely bad for you and has a noticeable chance of killing you in a matter of days if it gets out of hand.
More than you ever wanted to know about insulin and weight. Some bodybuilding sites cover it in quite good detail as well.
|
|
|
Post by babaoriley on Jul 13, 2016 1:20:26 GMT -5
Although a bit repetitive (not necessarily a bad thing), Mike packed in a whole lot of info in 24 minutes or so, and he did it quite smoothly and professionally.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 13, 2016 9:25:30 GMT -5
Forgive me as I don't understand the weight gain part. Why is it common to gain weight? I have taken medication that made me want to eat more and I did and gained weight. It's because diabetes is caused by an insulin deficiency - relative deficiency for Type 2 and absolute deficiency for Type 1, so the body cannot efficiently move glucose from the blood for energy. The body's response to an glucose deficit is to make you eat more which is problematic for diabetics because it means they overeat since only a percentage of the glucose gets through and the rest gets stuck in the blood and taken out by the kidneys. Now you start adding external insulin - suddenly the glucose is no longer getting trapped and your numbers improve. You now have enough for your energy requirements plus extra to store away as fat and you gain weight. Eventually the body recalibrates and the weight gain slows but by then you are several pounds past where you used to be. Diet and weight gain are finely balanced for insulin users because insulin with it's IGF-1 link is such a powerful hormone. Most of the weight gain from insulin is fat but some is muscle and that comes from the IGF-1 side (some bodybuilders take insulin for weight gain). Weight gain is commonly associated with improved HbA1c and you often see it when people go on pumps for the first time. The flip side is weight loss from diabulimia which is mostly Type 1 where you reduce insulin to increase glucose levels and skirt the edge of DKA. This turns loose ketosis that has about as much similarity to the ketosis you see in Atkins as a sabre toothed tiger has to a pussy cat. You can eat like a horse (actually you have to) and lose 10% of your bodyweight in a couple of weeks. Needless to say this is extremely bad for you and has a noticeable chance of killing you in a matter of days if it gets out of hand.
More than you ever wanted to know about insulin and weight. Some bodybuilding sites cover it in quite good detail as well. Thanks for the explanation. A lot of professional body builders use insulin (with steroids) to get to their freakish sizes. My old roommate used to tell me that insulin gave him a bit of an advantage in the gym. I know that is open for discussion.
|
|
|
Post by peppy on Jul 13, 2016 11:02:05 GMT -5
Although a bit repetitive (not necessarily a bad thing), Mike packed in a whole lot of info in 24 minutes or so, and he did it quite smoothly and professionally. agreed. Some new information also passed on by Mike. He said 70% of scripts are being covered by insurance. not going to renegotiate with insurers presently. He seemed to indicate, price will stay where it is. If that is the case and afrezza gets scripts, that is revenue with a good mark up.
wsw.com/webcast/cantor4/mnkd/ investors.mannkindcorp.com/events.cfm?EventType=Webcast
|
|
|
Post by bradleysbest on Jul 13, 2016 11:32:52 GMT -5
I can see a price decrease if scripts do not pick up. I see this a sign of Mike having confidence in his sales team. A steady increase in scripts during the next 2 quarters will go a long way for everyone involved. Agree with those that believe Mike should be doing ALL the public speaking for the company!
|
|
|
Post by kbrion77 on Jul 13, 2016 11:47:52 GMT -5
I can see a price decrease if scripts do not pick up. I see this a sign of Mike having confidence in his sales team. A steady increase in scripts during the next 2 quarters will go a long way for everyone involved. Agree with those that believe Mike should be doing ALL the public speaking for the company! I don't know all the economics behind the COGS or actual product profit and maybe if I did my point of view would change but in my opinion they have one shot for the re-launch. If scripts don't pick up would they even have time to lower price? I was hoping the focus would be 1. Dedicated Sales Force (check), 2. Lower price to undercut existing rapid treatments and 3. Slight label enhancements. They absolutely have to come out of the gate swinging the first couple months and as Mike alluded to yesterday a foreign deal will probably only come if sales show trajectory. There is way too much riding on this company to have any type of hiccup in the re-launch and I would certainly blast them if 3 months from now they decided to lower the price because of slow scripts.
|
|
|
Post by bradleysbest on Jul 13, 2016 11:53:09 GMT -5
Agree I also would like to see a price decrease now to get scripts up. Valid points & I hope 2.0 gets off the ground fast.
|
|
|
Post by mnkdorbust on Jul 13, 2016 12:06:47 GMT -5
His comments on why lowering the price won't really matter currently made sense to me, however so did adding to my position when the price was in the $7 range.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 13, 2016 12:21:54 GMT -5
His comments on why lowering the price won't really matter currently made sense to me, however so did adding to my position when the price was in the $7 range. I think the lesson learned at adding at $7 is understanding a Market Cap. I unfortunately learned the hard way too. The current market cap could even be debated.
|
|
|
Post by babaoriley on Jul 13, 2016 15:52:32 GMT -5
His comments on why lowering the price won't really matter currently made sense to me, however so did adding to my position when the price was in the $7 range. Loved the second part of your comment, mnkdorbust, very funny! As to the first part, I am still trying to make sense of it. That thing about no demand being the reason that they don't think lowering the price would help made no sense to me. I don't think there would be much (any) demand for a Toyota Corolla at $75,000, but lower the price to $20,000, and well....
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 13, 2016 15:55:54 GMT -5
His comments on why lowering the price won't really matter currently made sense to me, however so did adding to my position when the price was in the $7 range. Loved the second part of your comment, mnkdorbust, very funny! As to the first part, I am still trying to make sense of it. That thing about no demand being the reason that they don't think lowering the price would help made no sense to me. I don't think there would be much (any) demand for a Toyota Corolla at $75,000, but lower the price to $20,000, and well.... May be it meant - there are only few prescriptions and 7 to 8 pre auth are getting approval so why bother . Even if the price is reduced docs should still rx and they don't look at the price for rx
|
|
|
Post by mnkdorbust on Jul 13, 2016 16:18:18 GMT -5
Loved the second part of your comment, mnkdorbust, very funny! As to the first part, I am still trying to make sense of it. That thing about no demand being the reason that they don't think lowering the price would help made no sense to me. I don't think there would be much (any) demand for a Toyota Corolla at $75,000, but lower the price to $20,000, and well.... May be it meant - there are only few prescriptions and 7 to 8 pre auth are getting approval so why bother . Even if the price is reduced docs should still rx and they don't look at the price for rx I took away that once the price is out there it's a lot of work and resources to change it (which may or may not have any impact on placement, reimbursement, etc.) which they are running thin currently and they want their efforts focused on educating the DR's and creating a demand for Afrezza. There was also a post months if not a year ago that i haven't been able to find again that was about 3 paragraphs explaining why there is more to all of the inter workings of drug placement, etc. than price. It was a tread or discussion on price. Disclaimer that it was something i read on the internet and we know how internet advice/comments can be I would like to see the price lowered as well but i'm just an armchair quarterback with no experience in the area. I agree with your Corolla example however, commodities and medication are different.
|
|
|
Post by matt on Jul 13, 2016 16:21:19 GMT -5
It is important to remember that price means different things to different people. To self-pay patients with no insurance of any type the retail price matters but most patients have some form of coverage. For those people, many only see the co-pay and it may not be different regardless of what drug is involved so they don't care about the final cost (although the PBM does). Unless Mannkind is willing and able to make Afrezza cheaper than other fast acting insulins, and thereby capture tier 1 formulary positions, much of the "cost savings" will accrue to managed care companies and not to the benefit of the patient. That is not what the game is about.
|
|